论文部分内容阅读
目的:观察舒血宁注射液联合格列齐特治疗2型糖尿病的临床疗效,及对同型半胱氨酸和胱抑素C水平的影响,探讨其作用机制。方法:2型糖尿病患者60例随机分为观察组和对照组各30例。对照组给予格列齐特降糖治疗,观察组在此基础上给加用舒血宁注射液治疗。疗程均为2周。比较两组疗效、药品不良反应,以及治疗前后患者同型半胱氨酸(Hcy)、胱抑素C(Cys C)和血糖(FBG、PBG)水平变化。结果:观察组总有效率为96.67%,明显高于对照组的63.33%(P<0.05)。治疗后,两组患者的血糖以及Hcy、Cys C水平均较治疗前明显下降(P<0.05),且观察组上述指标均低于对照组(P<0.05)。两组患者药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:舒血宁注射液对2型糖尿病患者有较好疗效,可以有效降低同型半胱氨酸和胱抑素C水平,更好的控制血糖。
Objective: To observe the clinical efficacy of Shuxuening injection combined with gliclazide in the treatment of type 2 diabetes mellitus (T2DM) and its effect on the levels of homocysteine and cystatin C and its mechanism of action. Methods: Sixty patients with type 2 diabetes were randomly divided into observation group and control group, 30 cases each. The control group was given Gliclazide hypoglycemic treatment, the observation group on the basis of this treatment with Shuxuening injection. The course of treatment is 2 weeks. The curative effect, adverse drug reaction and the levels of Hcy, Cys C and FBG in patients before and after treatment were compared. Results: The total effective rate in observation group was 96.67%, which was significantly higher than that in control group (63.33%, P <0.05). After treatment, the levels of blood glucose, Hcy and Cys C in both groups were significantly lower than those before treatment (P <0.05), and the above indexes in the observation group were lower than those in the control group (P <0.05). Two groups of patients with adverse drug reactions, the difference was not statistically significant (P> 0.05). Conclusion: Shuxuening injection in patients with type 2 diabetes has a good effect, can effectively reduce the homocysteine and cystatin C levels, better control of blood glucose.